157284-96-3

Basic information

• Product Name: N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
• Synonyms: 7H-pyrrolo[2,3-d]pyrimidin-4-amine, N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-; N-Butyl-N-ethyl-7-mesityl-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
• CAS NO: 157284-96-3
• Molecular Formula: C₂₄H₃₄N₄
• Molecular Weight: 378.5536
• Mol File: 157284-96-3.mol

Chemical Properties

• Boiling Point: 437.2°C at 760 mmHg
• Flash Point: 218.2°C
• Density: 1.05g/cm³
• Vapor Pressure: 7.63E-08mmHg at 25°C
• Refractive Index: 1.574
• Storage Temp.: 2-8°C
• Solubility: DMSO: ~24?mg/mL, soluble
• PKA: 7.10±0.30(Predicted)
• CAS DataBase Reference: N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine(157284-96-3)
• EPA Substance Registry System: N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine(157284-96-3)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 157284-96-3(Hazardous Substances Data)

Relevant articles and documents

Pyrrolopyrimidines as CRF antagonists

The compounds of the formula wherein R1, R2, R3, R4, R5and R6are as defined herein, are useful in the treatment of stress-related and other diseases. These compounds have corticotropin-releasing factor antagonist activity and as such are of use in the treatment of stress and anxiety related, and other disorders.

Use of CRF antagonists and renin-angiotensin system inhibitors

The present invention relates to compositions and methods of achieving a therapeutic effect including, but not limited to, the treatment of congestive heart failure or hypertension in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist and a renin-angiotensin system (RAS) inhibitor.

QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death

A method of preventing sudden death which comprises administering to a mammal, including a human, a therapeutically effective amount of a corticotropin releasing factor antagonist.

New uses for corticotropin releasing factor antagonists

A method of treating, preventing or inhibiting a disorder selected from the group consisting of cardiovascular or heart related diseases such as stroke, hypertension, tachycardia, and congestive heart failure, osteoporosis, premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus, and colonic hypersensitivity associated with psychopathological disturbance and stress, comprising administering to a mammal, including a human, in need of such treatment a therapeutically effective amount of a compound of the formula or pharmaceutically acceptable salt thereof, wherein A, B, D, E, Y, Z, R3, R4, and R5 are as defined herein.

PYRAZOLOPYRIMIDINES FOR TREATMENT OF CNS DISORDERS

This invention relates to the use of pyrazolopyrimidines and pyrrolopyrimidine of, respectively, the general formula STR1 wherein A, X, R 3, R 4 and R 5 are as defined below, and the pharmaceutically acceptable salts of such compounds, to treat, prevent or inhibit certain neuronal and other disorders.

Methods of administering CRF antagonists

Compounds of the formula STR1 wherein B, R3, R4, R5 and R6 are as defined herein with reference to formula IX have corticotropin-releasing factor antagonist activity and as such are of use in the treatment of panics, phobias and other stress-related disorders.